開拓藥業-B(09939.HK)擬先舊後新配售1820萬股及股東郭創新出售370萬股 籌資11.6億港元用於普克魯胺開發及其他用途
格隆匯5月27日丨開拓藥業-B(09939.HK)公吿,於2021年5月26日,公司、賣方KT International Investment Limited(由公司聯合創始人、董事會主席、執行董事及主要股東童友之博士全資擁有)及售股股東KG Development Limited(由公司聯合創始人及主要股東郭創新博士全資擁有)與配售代理訂立協議。
據此,(i)賣方同意出售,而配售代理同意促使買方按每股股份64.50港元(較5月26日收市價每股70.70港元折讓約8.8%)的價格購買賣方持有的合共1820萬股股份或(倘未能成功促使買方購買)自行購買該等股份,相當於公司已發行股本約4.9%;(ii)賣方有條件同意訂立認購協議作為委託人按認購價(相當於配售價每股股份64.50港元)認購,而公司有條件同意發行1820萬股新股份;及(iii)售股股東同意出售,而配售代理同意促使買方按每股股份64.50港元的價格購買或(倘未能成功促使買方購買)自行購買合共370萬股股份,相當於已發行股本約1.0%。
認購事項的所得款項淨額估計約為11.6億港元。公司擬將認購事項全部所得款項淨額用於普克魯胺開發及商業化以及營運資金以作一般公司用途。
公司表示,進行配售事項及認購事項旨在補充集團擴展計劃及增長策略的長期資金。董事認為,配售事項及認購事項亦將為公司提供進一步集資的機會,同時擴大公司的股東基礎及資本基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.